Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- streptozocin
- Y-90 Zevalin (ibritumomab)
Interactions between your drugs
streptozocin ibritumomab tiuxetan
Applies to: streptozocin, Y-90 Zevalin (ibritumomab)
MONITOR: The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow, gastrointestinal tract and heart.
MANAGEMENT: Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.
References (9)
- (2001) "Product Information. Paraplatin (carboplatin)." Bristol-Myers Squibb
- (2001) "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb
- (2022) "Product Information. Fluorouracil (fluorouracil)." Roche Laboratories
- (2001) "Product Information. Zanosar (streptozocin)." Pharmacia and Upjohn
- (2001) "Product Information. Ellence (epirubicin)." Pharmacia and Upjohn
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- EMEA. European Medicines Agency (2007) EPARs. European Union Public Assessment Reports. http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid
- Cerner Multum, Inc. "Australian Product Information."
- Agencia Española de Medicamentos y Productos Sanitarios Healthcare (2008) Centro de información online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Xeloda
Xeloda is used to treat breast and colorectal cancers. Learn about side effects, interactions and ...
Lynparza
Lynparza (olaparib) is used to treat ovarian cancer, breast cancer, pancreatic cancer, and prostate ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Abraxane
Abraxane is an antineoplastic medication used in the treatment breast cancer. Learn about side ...
Gemzar
Gemzar is used to treat cancers of the pancreas, lung, breasts and ovaries. Learn about side ...
Afinitor
Afinitor prevents the growth of cancer cells and is used to treat advanced kidney cancer. Learn ...
Onivyde
Onivyde (irinotecan liposomal) is an injectable prescription chemotherapy medicine that may be used ...
Tarceva
Tarceva (erlotinib) is a chemotherapy medicine used in the treatment of non-small cell lung cancer ...
Sutent
Sutent is a cancer medicine that is used to treat certain types of advanced or progressive tumors ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.